{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T20:10:31Z","timestamp":1790539831510,"version":"4.1.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.xphs.2018.08.025","type":"journal-article","created":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T19:18:37Z","timestamp":1536434317000},"page":"2983-2991","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Methadone Metabolism and Drug-Drug Interactions: In\u00a0Vitro and In\u00a0Vivo Literature Review"],"prefix":"10.1016","volume":"107","author":[{"given":"Donna A.","family":"Volpe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrahas G.","family":"Sahajwalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Islam R.","family":"Younis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2018.08.025_bib1","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000018936","article-title":"L-Methadone and D,L-methadone in methadone maintenance treatment: a comparison of therapeutic effectiveness and plasma concentrations","volume":"4","author":"de Vos","year":"1998","journal-title":"Eur Addict Res"},{"key":"10.1016\/j.xphs.2018.08.025_bib2","doi-asserted-by":"crossref","first-page":"PL45","DOI":"10.1016\/0024-3205(94)00937-6","article-title":"The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine","volume":"56","author":"Kristensen","year":"1995","journal-title":"Life Sci"},{"key":"10.1016\/j.xphs.2018.08.025_bib3","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00003088-200241140-00003","article-title":"Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence","volume":"41","author":"Eap","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.xphs.2018.08.025_bib4","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/cpt1973143338","article-title":"Methadone binding to human plasma proteins","volume":"14","author":"Olsen","year":"1973","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.xphs.2018.08.025_bib5","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.clinbiochem.2005.09.009","article-title":"Free and bound enantiomers of methadone and its metabolite, EDDP in methadone maintenance treatment: relationship to dosage?","volume":"38","author":"Lehotay","year":"2005","journal-title":"Clin Biochem"},{"key":"10.1016\/j.xphs.2018.08.025_bib6","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1128\/AAC.02262-12","article-title":"Pharmacokinetic interaction between telaprevir and methadone","volume":"57","author":"van Heeswijk","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.xphs.2018.08.025_bib7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/00007691-199606000-00001","article-title":"Stereoselective pharmacokinetics of methadone in chronic pain patients","volume":"18","author":"Kristensen","year":"1996","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.xphs.2018.08.025_bib8","doi-asserted-by":"crossref","first-page":"e19527","DOI":"10.1371\/journal.pone.0019527","article-title":"Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response","volume":"6","author":"Fonseca","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.xphs.2018.08.025_bib9","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.drugalcdep.2006.12.018","article-title":"Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment","volume":"89","author":"P\u00e9rez de los Cobos","year":"2007","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.xphs.2018.08.025_bib10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/JCP.0b013e318192eb00","article-title":"Major depressive disorder and patient satisfaction in relation to methadone pharmacokinetics and pharmacodynamics in stabilized methadone maintenance patients","volume":"29","author":"Elkader","year":"2009","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.xphs.2018.08.025_bib11","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2125.2004.02221.x","article-title":"Subjective and physiological responses among racemic-methadone maintenance patients in relation to relative (S)- vs. (R)-methadone exposure","volume":"58","author":"Mitchell","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.xphs.2018.08.025_bib12","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.clpt.2005.08.011","article-title":"Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment","volume":"78","author":"Crettol","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.xphs.2018.08.025_bib13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/J354v19n04_05","article-title":"Pharmacokinetics of methadone","volume":"19","author":"Lugo","year":"2005","journal-title":"J\u00a0Pain Palliat Care Pharmacother"},{"key":"10.1016\/j.xphs.2018.08.025_bib14","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.clpt.2006.09.012","article-title":"ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment","volume":"80","author":"Crettol","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.xphs.2018.08.025_bib15","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/chir.10303","article-title":"Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19","volume":"16","author":"Gerber","year":"2004","journal-title":"Chirality"},{"key":"10.1016\/j.xphs.2018.08.025_bib16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1742-7843.2010.00628.x","article-title":"Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation","volume":"108","author":"Chang","year":"2010","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.xphs.2018.08.025_bib17","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/ALN.0b013e3181642938","article-title":"Role of CYP2B6 in stereoselective human methadone metabolism","volume":"108","author":"Totah","year":"2008","journal-title":"Anesthesiology"},{"key":"10.1016\/j.xphs.2018.08.025_bib18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1021\/tx950116m","article-title":"Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes","volume":"9","author":"Iribarne","year":"1996","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.xphs.2018.08.025_bib19","first-page":"1347","article-title":"The involvement of cytochrome P450 3A4 in the N-demethylation of L-\u03b1-acetylmethadol (LAAM), norlaam, and methadone","volume":"25","author":"Moody","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.xphs.2018.08.025_bib20","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1365-2125.1999.00921.x","article-title":"Methadone N-demethylation in human liver microsomes, lack of stereoselectivity and involvement of CYP3A4","volume":"47","author":"Foster","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.xphs.2018.08.025_bib21","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/jpet.106.117580","article-title":"Enantiomeric metabolic interactions and stereoselective human methadone metabolism","volume":"321","author":"Totah","year":"2007","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.xphs.2018.08.025_bib22","first-page":"32","article-title":"Role of CYP2B6 polymorphism in the metabolism and pharmacokinetics of methadone enantiomers","volume":"109","author":"Somogyi","year":"2011","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.xphs.2018.08.025_bib23","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.clpt.2004.05.003","article-title":"Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone","volume":"76","author":"Kharasch","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.xphs.2018.08.025_bib24","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1124\/dmd.109.027854","article-title":"Methadone induces the expression of hepatic drug-metabolizing enzymes through the activation of pregnane X receptor and constitutive androstane receptor","volume":"37","author":"Tolson","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.xphs.2018.08.025_bib25","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1213\/ANE.0b013e3182918252","article-title":"Mechanism of autoinduction of methadone N-demethylation in human hepatocytes","volume":"117","author":"Campbell","year":"2013","journal-title":"Anesth Analg"},{"key":"10.1016\/j.xphs.2018.08.025_bib26","doi-asserted-by":"crossref","first-page":"4928","DOI":"10.1002\/jps.21770","article-title":"Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in\u00a0vitro and in\u00a0vivo evaluation","volume":"98","author":"Hassan","year":"2009","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2018.08.025_bib27","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1159\/000107104","article-title":"In\u00a0vitro P-glycoprotein-mediated transport of (R)-, (S)-, (R,S)-methadone, LAAM and their main metabolites","volume":"80","author":"Crettol","year":"2007","journal-title":"Pharmacology"},{"key":"10.1016\/j.xphs.2018.08.025_bib28","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1017\/S1461145709990848","article-title":"Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)","volume":"13","author":"Tournier","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.xphs.2018.08.025_bib29","first-page":"954","article-title":"Methadone inhibits rhodamine 123 transport in Caco-2 cells","volume":"29","author":"St\u00f6rmer","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.xphs.2018.08.025_bib30","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s00213-003-1718-1","article-title":"Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood-brain barrier of Abcb1a gene knockout mice","volume":"173","author":"Wang","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.xphs.2018.08.025_bib31","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.bcp.2003.08.027","article-title":"Variable modulation of opioid brain uptake by P-glycoprotein in mice","volume":"67","author":"Dagenais","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.xphs.2018.08.025_bib32","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bcp.2015.03.007","article-title":"Influence of HIV antiretrovirals on methadone N-demethylation and transport","volume":"95","author":"Campbell","year":"2015","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.xphs.2018.08.025_bib33","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/clpt.2008.104","article-title":"Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance","volume":"84","author":"Kharasch","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.xphs.2018.08.025_bib34","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1124\/dmd.113.053991","article-title":"Cytochrome P4503A does not mediate the interaction between methadone and ritonavir-lopinavir","volume":"41","author":"Kharasch","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.xphs.2018.08.025_bib35","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1365-2125.2003.02053.x","article-title":"The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone","volume":"57","author":"Kharasch","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.xphs.2018.08.025_bib36","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1093\/hmg\/ddn122","article-title":"ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence","volume":"17","author":"Levran","year":"2008","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.xphs.2018.08.025_bib37","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.clpt.2006.09.011","article-title":"ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals","volume":"80","author":"Coller","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.xphs.2018.08.025_bib38","first-page":"53","article-title":"ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics","volume":"5","author":"Barratt","year":"2012","journal-title":"Pharmgenomics Pers Med"},{"key":"10.1016\/j.xphs.2018.08.025_bib39","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1046\/j.1365-2125.1999.00974.x","article-title":"Population pharmacokinetics of methadone in opiate users, characterization of time-dependent changes","volume":"48","author":"Rostami-Hodjegan","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.xphs.2018.08.025_bib40","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1046\/j.1360-0443.2000.951217717.x","article-title":"Population-based pharmacokinetic approach for methadone monitoring of opiate addicts, potential clinical utility","volume":"95","author":"Wolff","year":"2000","journal-title":"Addiction"},{"key":"10.1016\/j.xphs.2018.08.025_bib41","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2125.2008.03312.x","article-title":"Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment","volume":"67","author":"Shiran","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.xphs.2018.08.025_bib42","doi-asserted-by":"crossref","first-page":"977","DOI":"10.2217\/pgs.14.19","article-title":"Assessment of CYP450 genetic variability effect on methadone dose and tolerance","volume":"15","author":"Tsai","year":"2014","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.xphs.2018.08.025_bib43","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1369-1600.2011.00349.x","article-title":"CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction","volume":"18","author":"Levran","year":"2013","journal-title":"Addict Biol"},{"key":"10.1016\/j.xphs.2018.08.025_bib44","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/FTD.0000000000000437","article-title":"Combined effect of CYP2B6 genotype and other candidate genes on a steady-state serum concentration of methadone in opioid maintenance treatment","volume":"39","author":"Kringen","year":"2017","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.xphs.2018.08.025_bib45","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/JCP.0b013e318222b5dd","article-title":"CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone S-enantiomer","volume":"31","author":"Wang","year":"2011","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.xphs.2018.08.025_bib46","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/FPC.0b013e32835cb2e2","article-title":"Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels, a CYP2B6 gene resequencing study","volume":"23","author":"Dobrinas","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.xphs.2018.08.025_bib47","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00004714-200104000-00016","article-title":"Cytochrome P4502D6 genotype and methadone steady-state concentrations","volume":"21","author":"Eap","year":"2001","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.xphs.2018.08.025_bib48","doi-asserted-by":"crossref","first-page":"410","DOI":"10.5414\/CPP45410","article-title":"Lack of influence of CYP2D6 genotype on the clearance of (R)-, (S)- and racemic-methadone","volume":"45","author":"Coller","year":"2007","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.xphs.2018.08.025_bib49","doi-asserted-by":"crossref","first-page":"237","DOI":"10.36076\/ppj.2008\/11\/237","article-title":"Variations in opioid responsiveness","volume":"11","author":"Smith","year":"2008","journal-title":"Pain Physician"},{"key":"10.1016\/j.xphs.2018.08.025_bib50","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archinternmed.2010.26","article-title":"Substitution of (R,S)-methadone by (R)-methadone, impact on QTc interval","volume":"170","author":"Ansermot","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.xphs.2018.08.025_bib51","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/sj.clpt.6100120","article-title":"Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers","volume":"81","author":"Eap","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.xphs.2018.08.025_bib52","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/jcph.1","article-title":"Role of cytochrome P4502B6 in methadone metabolism and clearance","volume":"53","author":"Kharasch","year":"2013","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.xphs.2018.08.025_bib53","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/clpt.2011.276","article-title":"Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics","volume":"91","author":"Kharasch","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.xphs.2018.08.025_bib54","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0009-9236(98)90089-3","article-title":"The effect of fluconazole on the clinical pharmacokinetics of methadone","volume":"63","author":"Cobb","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.xphs.2018.08.025_bib55","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1128\/AAC.00559-06","article-title":"Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy","volume":"51","author":"Liu","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.xphs.2018.08.025_bib56","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.clpt.2004.03.007","article-title":"Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone","volume":"76","author":"Benmebarek","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.xphs.2018.08.025_bib57","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1097\/01.aids.0000183628.20041.f2","article-title":"Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction","volume":"19","author":"Friedland","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.xphs.2018.08.025_bib58","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1592\/phco.24.13.1110.38091","article-title":"Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects","volume":"24","author":"Hendrix","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.xphs.2018.08.025_bib59","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00228-014-1789-4","article-title":"Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy","volume":"71","author":"Hulskotte","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.xphs.2018.08.025_bib60","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1128\/AAC.04046-14","article-title":"Effect of steady-state faldaprevir on the pharmacokinetics of steady-state methadone and buprenorphine-naloxone in subjects receiving stable addiction management therapy","volume":"59","author":"Joseph","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.xphs.2018.08.025_bib61","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1177\/0091270009360981","article-title":"Effect of raltegravir on the pharmacokinetics of methadone","volume":"50","author":"Anderson","year":"2010","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.xphs.2018.08.025_bib62","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1128\/AAC.00478-15","article-title":"Assessment of drug-drug interactions between daclatasvir and methadone or buprenorphine\/naloxone","volume":"59","author":"Garimella","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.xphs.2018.08.025_bib63","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1592\/phco.24.11.970.36141","article-title":"Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R-, and S-methadone","volume":"24","author":"Smith","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.xphs.2018.08.025_bib64","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.drugalcdep.2013.08.009","article-title":"Dolutegravir does not affect methadone pharmacokinetics in opioid-dependent, HIV-seronegative subjects","volume":"133","author":"Song","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.xphs.2018.08.025_bib65","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/bdd.482","article-title":"Pharmacokinetic interaction of nelfinavir and methadone in intravenous drug users","volume":"27","author":"Hsyu","year":"2006","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.xphs.2018.08.025_bib66","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/10550490490436037","article-title":"Drug interactions between opioids and antiretroviral medications, interaction between methadone, LAAM, and nelfinavir","volume":"13","author":"McCance-Katz","year":"2004","journal-title":"Am J Addict"},{"key":"10.1016\/j.xphs.2018.08.025_bib67","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/10550490500419029","article-title":"Drug interactions between opioids and antiretroviral medications, interaction between methadone, LAAM, and delavirdine","volume":"15","author":"McCance-Katz","year":"2006","journal-title":"Am J Addict"},{"key":"10.1016\/j.xphs.2018.08.025_bib68","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00228-007-0299-z","article-title":"Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily","volume":"63","author":"Arroyo","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.xphs.2018.08.025_bib69","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1086\/322519","article-title":"Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users","volume":"33","author":"Clarke","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.xphs.2018.08.025_bib70","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1128\/AAC.48.11.4148-4153.2004","article-title":"Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients","volume":"48","author":"Stocker","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.xphs.2018.08.025_bib71","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.drugalcdep.2012.05.009","article-title":"Effect of lersivirine co-administration on pharmacokinetics of methadone in healthy volunteers","volume":"126","author":"Vourvahis","year":"2012","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.xphs.2018.08.025_bib72","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/0091270007310387","article-title":"Pharmacokinetic and pharmacodynamic study of the concomitant administration of methadone and TMC125 in HIV-negative volunteers","volume":"48","author":"Sch\u00f6ller-Gy\u00fcre","year":"2008","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.xphs.2018.08.025_bib73","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1046\/j.1365-2125.2001.00342.x","article-title":"The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz","volume":"51","author":"Clarke","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.xphs.2018.08.025_bib74","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/10550490290088072","article-title":"Modified directly observed therapy (MDOT) for injection drug users with HIV disease","volume":"11","author":"McCance-Katz","year":"2002","journal-title":"Am J Addict"},{"key":"10.1016\/j.xphs.2018.08.025_bib75","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/jcph.222","article-title":"The effect of rilpivirine on the pharmacokinetics of methadone in HIV-negative volunteers","volume":"54","author":"Crauwels","year":"2013","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.xphs.2018.08.025_bib76","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1086\/376907","article-title":"The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients","volume":"37","author":"McCance-Katz","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.xphs.2018.08.025_bib77","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00042560-200106010-00010","article-title":"Effect of ritonavir\/saquinavir on stereoselective pharmacokinetics of methadone, results of AIDS Clinical Trials Group (ACTG) 401","volume":"27","author":"Gerber","year":"2001","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.xphs.2018.08.025_bib78","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1369-1600.2009.00158.x","article-title":"Effect of saquinavir\/ritonavir (1000\/100 mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapy","volume":"14","author":"Jamois","year":"2009","journal-title":"Addict Biol"},{"key":"10.1016\/j.xphs.2018.08.025_bib79","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/0091270003262956","article-title":"The effects of once-daily saquinavir\/minidose ritonavir on the pharmacokinetics of methadone","volume":"44","author":"Shelton","year":"2004","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.xphs.2018.08.025_bib80","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/0091270010365558","article-title":"Pharmacokinetic interactions between darunavir\/ritonavir and opioid maintenance therapy using methadone or buprenorphine\/naloxone","volume":"51","author":"Sekar","year":"2011","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.xphs.2018.08.025_bib81","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1086\/339541","article-title":"Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir","volume":"34","author":"Clarke","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.xphs.2018.08.025_bib82","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/00007691-200110000-00010","article-title":"Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir","volume":"23","author":"Bart","year":"2001","journal-title":"Ther Drug Monit"},{"issue":"S2","key":"10.1016\/j.xphs.2018.08.025_bib83","doi-asserted-by":"crossref","first-page":"S652","DOI":"10.1016\/S0168-8278(15)31041-2","article-title":"Evaluation of drug\u2013drug interactions between the fixed-dose combination of daclatasvir\/asunaprevir\/beclabuvir and methadone or buprenorphine\/naloxone","volume":"62","author":"Tao","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.xphs.2018.08.025_bib84","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1080\/10550490252801657","article-title":"The pharmacokinetics of methadone following co-administration with a lamivudine\/zidovudine combination tablet in opiate-dependent subjects","volume":"11","author":"Rainey","year":"2002","journal-title":"Am J Addict"},{"key":"10.1016\/j.xphs.2018.08.025_bib85","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/phar.1341","article-title":"Effect of ritonavir-boosted danoprevir, a potent hepatitis C virus protease inhibitor, on the pharmacokinetics of methadone in healthy subjects undergoing methadone maintenance therapy","volume":"34","author":"Moreira","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.xphs.2018.08.025_bib86","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhep.2015.01.026","article-title":"Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir\/ritonavir, ombitasvir, and dasabuvir","volume":"63","author":"Menon","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.xphs.2018.08.025_bib87","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1128\/AAC.01778-15","article-title":"Drug interactions with the direct-acting antiviral combination of ombitasvir and paritaprevir-ritonavir","volume":"60","author":"Badri","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.xphs.2018.08.025_bib88","doi-asserted-by":"crossref","first-page":"6154","DOI":"10.1128\/AAC.01229-13","article-title":"Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenance","volume":"57","author":"Bruce","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.xphs.2018.08.025_bib89","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/00042560-199808150-00004","article-title":"Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262)","volume":"18","author":"McCance-Katz","year":"1998","journal-title":"J\u00a0Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"10.1016\/j.xphs.2018.08.025_bib90","first-page":"619","article-title":"Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infection","volume":"5","author":"Schwartz","year":"1992","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.xphs.2018.08.025_bib91","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00228-009-0767-8","article-title":"Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy setting","volume":"66","author":"Haberl","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.xphs.2018.08.025_bib92","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/00126334-200007010-00008","article-title":"Interaction of methadone with didanosine and stavudine","volume":"24","author":"Rainey","year":"2000","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.xphs.2018.08.025_bib93","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1592\/phco.28.7.863","article-title":"Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects","volume":"28","author":"Cao","year":"2008","journal-title":"Pharmacotherapy"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354918305264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354918305264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:24:49Z","timestamp":1758360289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354918305264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":93,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0022354918305264"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2018.08.025","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Methadone Metabolism and Drug-Drug Interactions: In\u00a0Vitro and In\u00a0Vivo Literature Review","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2018.08.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the American Pharmacists Association.","name":"copyright","label":"Copyright"}]}}